-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The new crown recombinant protein vaccine (Chikweide®) jointly developed by the Institute of Microbiology of the Chinese Academy of Sciences and Zhifeilongkoma has been launched in Beijing.
On May 27, some scientific researchers from the Institute of Microbiology of the Chinese Academy of Sciences in the vaccine research and development base received the first injection at the "Chinese Academy of Sciences Vaccination Special" in Haidian District.
The new crown recombinant protein vaccine has received the support of the National Key Research and Development Program, the National Key Drug Research and Development Project of the Ministry of Science and Technology, and the pilot project of the Chinese Academy of Sciences.
It is one of the five vaccine technology routes deployed in my country.
On March 1, 2021, the new crown recombinant protein vaccine was approved for use in Uzbekistan.
Uzbekistan evaluated the vaccine as one of the safest and most effective vaccines in the world.
On March 10, the vaccine was approved for emergency use in China, and it has been injected in Anhui, Zhejiang, Jiangsu, Shandong, Guizhou, Hubei, Henan and other places.
On May 3, the first batch of COVID-19 recombinant protein vaccines was successfully produced off the assembly line in Beijing.
The vaccine is the fourth new coronavirus vaccine approved for emergency use in China, and it is also the first new coronavirus recombinant subunit protein vaccine approved for clinical use in the world.
The new crown recombinant protein vaccine uses a three-shot immunization procedure, and its technical principle is similar to that of the mature hepatitis B vaccine.
It is a new type of coronavirus spike glycoprotein receptor binding region NCP-RBD protein expressed by recombinant CHO cells using DNA recombination technology, purified and added with aluminum hydroxide adjuvant to make a suspension injection.
After vaccination, it can stimulate the body to produce immunity against the new coronavirus.
A phase II clinical trial conducted in adults aged 18-59 showed that the positive conversion rate of neutralizing antibody reached 83% after the subjects were vaccinated with 2 doses, and the positive conversion rate of neutralizing antibody reached 97% after the subjects were vaccinated with 3 doses.
%.No serious adverse reactions occurred after vaccination, which is in line with the characteristics of small adverse reactions of subunit vaccines, and the level of neutralizing antibodies produced is equivalent to the current international recombinant protein vaccines and mRNA new crown vaccines, reaching the international advanced level.
A phase I trial carried out in elderly people 60 years and older showed that after the subjects were vaccinated with 3 doses, the neutralizing antibody positive conversion rate reached 95%; no serious adverse reactions related to the vaccine occurred.
The vaccine production uses engineered cells (CHO) to produce recombinant proteins, and does not require high-grade biosafety laboratory production workshops.
The production process is stable and reliable.
Large-scale industrial production at home and abroad can be quickly realized, significantly reducing vaccine production costs and storage.
And convenient transportation.
As a national strategic scientific and technological force in the field of microbiology, the Institute of Microbiology of the Chinese Academy of Sciences has given orders and acted bravely, caring for the people's feelings of patients and the mission spirit of serving the country, relying on the institute's forward-looking technological layout and strong foundation formed by years of hard work The work has provided strong scientific and technological support for the national epidemic prevention and control work, and has submitted a satisfactory answer to the Party Central Committee and the people of the whole country.
The Institute of Microbiology will continue to make important contributions to safeguarding people’s lives and health and building a community of human health and health.
Open to reprint this article open to reprint: just leave a message in this article to inform
On May 27, some scientific researchers from the Institute of Microbiology of the Chinese Academy of Sciences in the vaccine research and development base received the first injection at the "Chinese Academy of Sciences Vaccination Special" in Haidian District.
The new crown recombinant protein vaccine has received the support of the National Key Research and Development Program, the National Key Drug Research and Development Project of the Ministry of Science and Technology, and the pilot project of the Chinese Academy of Sciences.
It is one of the five vaccine technology routes deployed in my country.
On March 1, 2021, the new crown recombinant protein vaccine was approved for use in Uzbekistan.
Uzbekistan evaluated the vaccine as one of the safest and most effective vaccines in the world.
On March 10, the vaccine was approved for emergency use in China, and it has been injected in Anhui, Zhejiang, Jiangsu, Shandong, Guizhou, Hubei, Henan and other places.
On May 3, the first batch of COVID-19 recombinant protein vaccines was successfully produced off the assembly line in Beijing.
The vaccine is the fourth new coronavirus vaccine approved for emergency use in China, and it is also the first new coronavirus recombinant subunit protein vaccine approved for clinical use in the world.
The new crown recombinant protein vaccine uses a three-shot immunization procedure, and its technical principle is similar to that of the mature hepatitis B vaccine.
It is a new type of coronavirus spike glycoprotein receptor binding region NCP-RBD protein expressed by recombinant CHO cells using DNA recombination technology, purified and added with aluminum hydroxide adjuvant to make a suspension injection.
After vaccination, it can stimulate the body to produce immunity against the new coronavirus.
A phase II clinical trial conducted in adults aged 18-59 showed that the positive conversion rate of neutralizing antibody reached 83% after the subjects were vaccinated with 2 doses, and the positive conversion rate of neutralizing antibody reached 97% after the subjects were vaccinated with 3 doses.
%.No serious adverse reactions occurred after vaccination, which is in line with the characteristics of small adverse reactions of subunit vaccines, and the level of neutralizing antibodies produced is equivalent to the current international recombinant protein vaccines and mRNA new crown vaccines, reaching the international advanced level.
A phase I trial carried out in elderly people 60 years and older showed that after the subjects were vaccinated with 3 doses, the neutralizing antibody positive conversion rate reached 95%; no serious adverse reactions related to the vaccine occurred.
The vaccine production uses engineered cells (CHO) to produce recombinant proteins, and does not require high-grade biosafety laboratory production workshops.
The production process is stable and reliable.
Large-scale industrial production at home and abroad can be quickly realized, significantly reducing vaccine production costs and storage.
And convenient transportation.
As a national strategic scientific and technological force in the field of microbiology, the Institute of Microbiology of the Chinese Academy of Sciences has given orders and acted bravely, caring for the people's feelings of patients and the mission spirit of serving the country, relying on the institute's forward-looking technological layout and strong foundation formed by years of hard work The work has provided strong scientific and technological support for the national epidemic prevention and control work, and has submitted a satisfactory answer to the Party Central Committee and the people of the whole country.
The Institute of Microbiology will continue to make important contributions to safeguarding people’s lives and health and building a community of human health and health.
Open to reprint this article open to reprint: just leave a message in this article to inform
